Based on typical FDA review timelines and the current progress of trials, analysts project: Phase 3 trial completion: Late 2025 to early 2026 FDA submission: First half of 2026 Potential FDA approval: Q3 2026 to Q1 2027 Commercial availability: 2-3 months post-approval The FDA has not granted any special designations (Breakthrough Therapy, Fast Track) for Retatrutides obesity indication, which may mean standard review timelines apply
Lack of association between fingernail selenium and thyroid cancer risk: A case-control study in French Polynesia
Studies have directly compared the effects of the two treatments on the risk of MASLD/MASH, with results showing that both can improve hepatic steatosis and liver enzymes, though the differences may not be statistically significant
The clinic is not built around a single service or weight-loss philosophy
I think that RFK and the [Make America Healthy Again] movement see peptides as part of a suite of compounds that, as they see it, have been kind of improperly restricted by the pharmaceutical industry
Vials wider than ~17mm, including most 10ml vials (typically ~24mm), will not fit these slots please measure before ordering